Fortress Biotech, Inc.

NASDAQ:FBIO

Biotechnology

Healthcare
$1.89 -1.79%

-$0.06 today

Market cap
$63.03M
Beta
1.23
P/E (TTM)
0.7
EPS (TTM)
$4.05
52W Low $1.70High $4.53

Volume 0.41M

Average 0.43M

FBIO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Fortress Biotech, Inc.NASDAQ: FBIO

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 54.2%

Gross margin was 54.2% in Q1 FY2026, down 9.3 pp from a year earlier. On a trailing-twelve-month basis it was 64.5%, up 3.3 pp year over year. Over 3 fiscal years it widened by 7.6 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
54.2%-12.0 pp QoQ
Last fiscal yearDec 2025
66.9%+3.1 pp YoY
LTMMar 2026
64.5%+3.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-9.3 pp——
1 year+3.1 pp——
3 years+7.6 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
66.9%
Year-over-year change
+3.1pp

Gross Margin vs competitors

How FBIO compares with its peers on the latest reported figures

  • FBIO's LTM Mar 2026 gross margin of 64.5% is the 3rd highest of the 5 companies compared; the peer median is 60.4%.
  • Its year-over-year change of +3.3 pp is the highest of 4, against a peer median of -4.9 pp.
  • Over three fiscal years its change of +7.6 pp compares with a peer median of -4.1 pp.
FBIO Competitors Peer median
Gross Margin for FBIO and competitors
Company Period LTM level YoY 3-year change
VXRTVaxart, Inc.LTM Mar 2026100.0% +0.0 pp+0.0 pp
TCRXTScan Therapeutics, Inc.LTM Mar 202692.4% -7.6 pp-27.8 pp
FBIOFortress Biotech, Inc.LTM Mar 202664.5% +3.3 pp+7.6 pp
NTRBNutriband Inc.LTM Apr 202628.4% -4.9 pp-8.3 pp
ADAGAdagene Inc.LTM Jun 2024-14.6% —+0.0 pp
RLMDRelmada Therapeutics, Inc.FY2025— ——
IMUXImmunic, Inc.FY2025— ——
PMVPPMV Pharmaceuticals, Inc.FY2025— ——
XBITXBiotech Inc.FY2025— ——
GANXGain Therapeutics, Inc.FY2025— ——
Peer median (excluding FBIO) 60.4%-4.9 pp-4.1 pp

Competitors are the stored peer set for FBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue68.79M75.74M84.51M57.68M63.26M
Cost of Revenue32.08M30.78M22.89M20.88M20.92M
Gross Profit36.71M44.97M61.62M36.8M42.34M
Gross Margin53.4%59.4%72.9%63.8%66.9%
Research & Development128.87M134.88M106.07M56.88M11.9M
Selling, General & Admin86.84M113.66M90.98M87.73M96.4M
Operating Expenses225.25M248.53M203.96M147.18M112.56M
Depreciation & Amortization6.79M9.35M6M4.46M4.66M
EBITDA(146.17M)(193.69M)(135.72M)(104.49M)(20.17M)
EBITDA Margin-212.5%-255.7%-160.6%-181.2%-31.9%
Operating Income(188.54M)(203.56M)(142.34M)(110.38M)(70.22M)
Operating Margin-274.1%-268.8%-168.4%-191.4%-111.0%
Interest Income649K1.4M3M2.68M2.49M
Interest Expense15.31M13.64M12.52M9.93M8.71M
Other Income / Expenses24.19M(9.9M)(11.29M)(10.16M)36.69M
Income Before Tax(164.35M)(213.46M)(153.63M)(120.54M)(33.54M)
Pre-Tax Margin-238.9%-281.8%-181.8%-209.0%-53.0%
Income Tax Expense473K449K521K312K(620K)
Net Income(64.7M)(86.58M)(60.64M)(46M)6.82M
Net Margin-94.1%-114.3%-71.7%-79.8%10.8%
EPS (Basic)(11.85)(14.55)(8.47)(2.69)(0.07)
EPS (Diluted)(11.85)(14.55)(8.47)(2.69)(0.07)
Weighted Avg Shares5.45M5.93M8.11M20.78M27.9M
Weighted Avg Shares (Diluted)5.45M5.93M8.11M20.78M279.02M

Fortress Biotech, Inc.

NASDAQ:FBIO

Intrinsic Alpha fair value

Locked

Current Price

$1.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.